Sign in to continue:

Friday, October 17th, 2025

Author: minichart

Market Updates

Yangzijiang Shipbuilding: Strategic Expansion and Strong Financials Drive 29% Upside Potential

minichart
September 13, 2024

Introduction Yangzijiang Shipbuilding (YZJSB) continues to assert its dominance in the shipbuilding sector, and with its recent strategic investments and strong financial outlook, the company presents an attractive investment opportunity for potential investors. In...

Continue Reading 0
Market Updates

Hanwha Aerospace’s Tender Offer for Dyna-Mac: A Growth Opportunity Amidst FPSO Market Surge

minichart
September 12, 2024

Company Highlights: Dyna-Mac Holdings (SGX: DMHL.SI), a Singapore-based leading fabricator of offshore topside modules, has recently captured significant attention following Hanwha Aerospace and Hanwha Ocean’s tender offer of SGD 0.60 per share, representing a...

Continue Reading 0
Market Updates

Investment Opportunities in Dyna-Mac, Food Empire, Q&M Dental, and Rex International: Strategic Moves and Market Outlook

minichart
September 12, 2024

Investment Recommendations Dyna-Mac Holdings: BUY (Potential upside with a possible offer increase) Food Empire: HOLD (Solid growth strategy but long-term horizons) Q&M Dental: HOLD (Strategic acquisition with moderate growth prospects) Rex International: HOLD (Short-term...

Continue Reading 0
Hong Kong stocksMarket Updates

Investment Opportunity: China Petroleum & Chemical Corp (Sinopec) – Buy Now Before the Rebound

minichart
September 12, 2024

Company Highlights: China Petroleum & Chemical Corp (Sinopec) is China’s second-largest integrated oil and gas operator and the largest refining player. With strong operations across both upstream and downstream segments, Sinopec remains well-positioned in...

Continue Reading 0
Market UpdatesSingapore SGX stocks

Singapore Exchange (SGX): Trading Volume Growth Spurs Price Rally

minichart
September 12, 2024

Company HighlightsThe focus of this investment report is on Singapore Exchange (SGX). The company is experiencing heightened trading volumes, with a positive outlook on its stock performance driven by various financial factors. Investment RecommendationThe...

Continue Reading 0
Market UpdatesSingapore SGX stocks

“Investment Opportunities: Dyna-Mac and InnoTek Lead the Charge in Singapore’s Stock Market”

minichart
September 12, 2024

Investment Report: This report covers Dyna-Mac Holdings and InnoTek Limited, with a focus on their financial performance, potential catalysts, and investment recommendations. It also includes insights into other top companies such as Jardine Matheson,...

Continue Reading 0
Market UpdatesSingapore SGX stocks

Hyphens Pharma International – A Healthy Pipeline Driving Revenue Growth and Profitability

minichart
September 12, 2024

Company Highlights: Hyphens Pharma International (HYP) has shown a strong performance in the first half of 2024, achieving record revenue of S$99.6 million, a significant 33.4% year-over-year (YoY) increase. The company’s growth was driven...

Continue Reading 0
Hong Kong stocksMarket UpdatesSingapore SGX stocks

Sinarmas Land Ltd and BeiGene Ltd Poised for Growth Amid Bullish Signals

minichart
September 12, 2024

Investment Recommendation: Sinarmas Land Ltd (SIN) and BeiGene Ltd (HKG: 6160) are both recommended buys, based on technical analysis indicating potential upward price movement. Investors are advised to take long positions on both stocks....

Continue Reading 0
Bursa KLSE stocksMarket Updates

Uchi Technologies, AppAsia, and Power Root: Top Investment Picks to Watch

minichart
September 12, 2024

Company Highlights: Uchi Technologies (7100) AppAsia (0119) Power Root (PWRT) Investment Recommendation: For Uchi Technologies and AppAsia, a Technical Buy is recommended, while Power Root is downgraded to Hold due to earnings struggles. Investment...

Continue Reading 0
Hong Kong stocksMarket Updates

Innovent Biologics: Pharma Giant in the Making with Strong Growth Prospects

minichart
September 12, 2024

Company Highlights: Innovent Biologics is evolving from a biotech company to a major pharmaceutical player in China, driven by its diverse drug pipeline. Key drugs such as Sintilimab, the company’s leading anti-PD-1 antibody, and...

Continue Reading 0